AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00328926
Drug: Luveris® 75 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 75 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and estradiol \[E2\] levels). Total duration will be of 3 treatment cycles.
Trial: NCT00328926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
Trial: NCT02388971
Drug: MLN1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN1202 solution
Trial: NCT02388971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN1202 placebo-matching solution
Trial: NCT02695797
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
Trial: NCT02828358
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02828358
Drug: Hydrocortisone Sodium Succinate
RxNorm normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT02828358
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO, IV
Trial: NCT02828358
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO, IV
Trial: NCT02828358
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO, NG
Trial: NCT02828358
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, PO
Trial: NCT02828358
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO, NG
Trial: NCT02330380
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive Methotrexate as detailed in the Group description.
Trial: NCT02628236
Drug: Aminolevulinic Acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
Trial: NCT02281643
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm
Trial: NCT00983177
Drug: lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose capsules twice daily
Trial: NCT02987985
Drug: Acetaminophen, gabapentin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 15 mg/kg, gabapentin 10 mg/kg
Trial: NCT02987985
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 15 mg/kg
Trial: NCT02987985
Drug: Fentanyl, Dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
Trial: NCT02987985
Drug: Sevoflurane, Fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
Trial: NCT05088343
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.
Trial: NCT00040391
Drug: Investigational drug
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00040391
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03025945
Drug: Nepafenac 0.3%
RxNorm normalized name: NEPAFENAC 0.3% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00829075
Drug: r-FSH
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00829075
Drug: HP-hMG
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00829075
Drug: r-FSH plus HP-hMG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02361502
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02257372
Drug: UMEC DPI
RxNorm normalized name: Umecta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The UMEC DPI will contain one blister strip which will have 30 blisters of UMEC as dry powder blended with lactose and magnesium stearate, with no companion strip. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously.
Trial: NCT02257372
Drug: Placebo DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The matching placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
Trial: NCT02257372
Drug: ICS/LABA medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will use ICS/LABA combinations that are approved for the treatment of COPD at approved doses and frequency including SERETIDE 500/50mcg twice daily, FSC 500/50 mcg twice daily generic products such as AIRFLUSAL FORSPIRO inhaler 500/50mcg twice daily or ROLENIUM ELPENHALER inhaler 500/50mcg twice daily and SYMBICORT TURBUHALER inhaler at doses of 200/6mcg twice daily and 400/12mcg twice daily. The ICS/LABA will be sourced from local commercial stock while on the study
Trial: NCT00003535
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with a recurrent/progressive high grade glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT03860753
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill capsules will look same as that of active drug.
Trial: NCT04136873
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching CVL-231
Trial: NCT01702987
Drug: statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: statin was given for 1 month to 21 patients
Trial: NCT03113240
Drug: Glutamin
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.
Trial: NCT01397370
Drug: GLPG0492
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT01397370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT03115177
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision for total shoulder arthroplasty.
Trial: NCT02086747
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml iv, 4 times a day for 72 hours
Trial: NCT02086747
Drug: Isotonic
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml iv, 4 times a day for 72 hours
Trial: NCT00111800
Drug: DEN 30 mg
RxNorm normalized name: adenosine monophosphate Injectable Solution [My-O-Den]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEN 30 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
Trial: NCT00111800
Drug: DEN 45 mg
RxNorm normalized name: adenosine monophosphate Injectable Solution [My-O-Den]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEN 45 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
Trial: NCT00428909
Drug: Imatinib/Acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02634853
Drug: Placebo Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution
Trial: NCT00004694
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00318630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will also receive placebo oral tablet.
Trial: NCT03924869
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT01961349
Drug: ICI35,868 (Diprivan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treated by Anaesthesiologist
Trial: NCT01961349
Drug: ICI35,868 (Diprivan) + EES0000645/A (SDS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treated by Endoscopist with EES0000645/A(SDS)
Trial: NCT00717405
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT01843842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and Efficiency of liquid dosage form
Trial: NCT01236690
Drug: Cinobufacin injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy
Trial: NCT02953340
Drug: SPI-2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
Trial: NCT02953340
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600mg/m\^2 IV infusion administered on Day 1 of each cycle
Trial: NCT02757105
Drug: BEKINDA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02757105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03282162
Drug: intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An identical amount of intranasal administration of placebo will be assigned to each subject.
Trial: NCT02385500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication.
Trial: NCT02126917
Drug: HC-ER + 40% Alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state
Trial: NCT02942914
Drug: LY3209590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02942914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02126917
Drug: HC-ER + 20% Alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state
Trial: NCT02126917
Drug: HC-ER + 0% Alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state
Trial: NCT03600480
Drug: NNC0174-0833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive increasing dose levels of 0.16 mg, 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg of NNC0174-0833 (subcutaneous \[s.c.\], in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time. Each participant will only be given one dose level.
Trial: NCT03600480
Drug: Placebo (NNC0174-0833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once weekly injections of NNC0174-0833 matched placebo.
Trial: NCT02168634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1cc normal saline, local injection
Trial: NCT03426722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 500mg TID(PO)
Trial: NCT04165772
Drug: capecitabine or 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines. If patient is unable to tolerate oral medication, infusional 5-FU is an acceptable alternative.
Trial: NCT01152840
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 10 mg po daily medication~* Treatments will be continued until any of the following events occur:~  * progression of disease,~ * the subject develops unacceptable toxicity,~ * consent to participate in the study is withdrawn.
Trial: NCT01854463
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elemental calcium 200mg per day per 24 weeks
Trial: NCT00001535
Drug: Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02249585
Drug: Deep neuromuscular blockade
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia induction with rocuronium 0.8mg/kg → maintenance with rocuronium 0.3mg/kg to maintain PTC 1-2 twitch
Trial: NCT03502395
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
Trial: NCT00753558
Drug: Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm #1: Oral gentamicin \& polymyxin E, gentamicin \& polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel.
Trial: NCT02761512
Drug: CJ-12420 50 mg QD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CJ-12420 50 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 50 mg.
Trial: NCT02761512
Drug: CJ-12420 100 mg QD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 100 mg.
Trial: NCT00614250
Drug: AVE0657
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules once a day at bedtime
Trial: NCT00614250
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules once a day at bedtime
Trial: NCT00006451
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006451
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02840695
Drug: bDMARD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.
Trial: NCT04560738
Drug: [14C]-CC-92480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03528343
Drug: Non-narcotic pain control
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education to use tylenol and motrin only for pain control unless this is unable to control pain. Rescue prescription provided.
Trial: NCT00496730
Drug: simvastatin (+) ezetimibe
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
Trial: NCT03782402
Drug: Cannabinoids
RxNorm normalized name: cannabinoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabinoids with THC and CBD versus placebo cannabinoids
Trial: NCT02317861
Drug: RDEA3170
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Treatment
Trial: NCT00761007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet matching the three dose levels of ibodutant, once daily
Trial: NCT03220542
Drug: Probiotics
RxNorm normalized name: probiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii
Trial: NCT03220542
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin
Trial: NCT03548935
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks.
Trial: NCT01432873
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge
Trial: NCT04596007
Drug: HEC83518 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose of HEC83518 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
Trial: NCT04596007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01594515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for oral administration
Trial: NCT04472585
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc Sulphate 20mg 3 times a day
Trial: NCT04472585
Drug: Placebo empty capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo empty capsule
Trial: NCT02833012
Drug: AC-1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1
Trial: NCT02833012
Drug: Axona
RxNorm normalized name: AXONA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1
Trial: NCT00296062
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase I: oral capecitabine twice daily on days 1-7 and 15-21.Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined.Phase II:receive capecitabine (at the MTD determined in phase I(odd-numbered courses)
Trial: NCT02009462
Drug: Artefill dermal filler
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.
Trial: NCT04315181
Drug: Opioid Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abuse liability evaluation.
Trial: NCT04315181
Drug: Sedatives
RxNorm normalized name: SEDATIVES/HYPONTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abuse liability evaluation.
Trial: NCT00679510
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablet 10 mgs once daily
Trial: NCT00679510
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01518972
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg
Trial: NCT01529502
Drug: Inhaled Nitric Oxide (iNO) administration
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
Trial: NCT01218464
Drug: Conventional plus MSC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 12 weeks.
Trial: NCT01218464
Drug: Conventional plus pacebo treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
Trial: NCT00510172
Drug: Prostacyclin, PGI2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ng/kg/min of epoprostenol (stable PGI2)
Trial: NCT04196075
Drug: Andrographis Paniculata
RxNorm normalized name: Andrographis paniculata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP as palliative treatment